Can Inavolisib be used as a targeted therapy for breast cancer?

Inavolisib (Inavolisib) is an oral small molecule PI3Kα selective inhibitor that mainly targets signaling pathway abnormalities caused by PIK3CA gene mutations. PIK3CAmutations are associated with breast cancer, especially hormone receptor-positive (HR+), human epidermal growth factor receptor 2negative (HER2-) common driver gene mutations in breast cancer, accounting for about 40% of such patients. Inhibitors targeting this target can effectively block the proliferation and survival signals of tumor cells. Therefore, as a PI3K inhibitor, inalise shows great potential in the field of targeted therapy of breast cancer.

Preclinical and early clinical trial data show that inaliset exhibits good anti-tumor activity against PIK3CA mutation-positive breast cancer cell lines and patients. Compared with traditional PI3K inhibitors, inaliset is more selective and has relatively lower side effects. In particular, the incidence of common adverse reactions such as diabetes and rash has been reduced, improving patient tolerance and compliance. This provides strong support for its use as a targeted therapeutic drug for breast cancer.

Currently, inaliset is undergoing multiple clinical trials in patients with advanced HR+/HER2- breast cancer to evaluate its efficacy in combination with endocrine therapy (such as aromatase inhibitors or fulvestrant) in inhibiting disease progression. Early data shows that the progression-free survival (PFS) of the combination treatment group is significantly prolonged, and the tumor response rate is also significantly improved, showing good clinical application prospects.

In general, as a new type of PI3Kα inhibitor, inalisate has the conditions to become a targeted therapeutic drug for breast cancer, especially suitable for PIK3CA mutation-positive HR+/HER2- patients. With the deepening of clinical trials, its safety and effectiveness will be further clarified, which is expected to bring new treatment options and better prognosis improvement to such patients.

Reference materials:https://www.drugs.com/